Atreca (NASDAQ:BCEL) stock is getting a boost on Tuesday as the company continues a recent rally connected to insider buying.
On Monday, shares of BCEL stock jumped nearly 14% after a series of filings with the U.S. Securities and Exchange Commission (SEC). Those revealed several leaders at the company buying and selling shares of BCEL stock.
Initially, that news sent BCEL stock higher. However, pre-market trading saw the company’s shares start to fall. Even so, that downward momentum didn’t last beyond pre-market trading with the company’s shares gaining again today.
Let’s go over that trading with a quick breakdown below!
Insider Trading of BCEL Stock
- General Counsel & Secretary Officer Courtney Phillips acquired 32,500 shares of the stock.
- CFO Herb Cross acquired 43,750 shares of the company’s stock.
- Chief Strategy Officer Tito Serafini acquired 43,750 shares of the company’s stock.
- President and CEO John Orwin acquired 435,000 shares of BCEL stock.
- Chief Science Officer Stephen Gould acquired 32,500 shares of the company’s stock.
Atreca is a biopharmaceutical company focused on the development of novel therapeutics. This has it targeting immune response in humans as a way to treat various diseases.
BCEL stock is up 4% as of Tuesday morning and is up 96.5% since the start of the year.
Investors on the lookout for all of the latest stock market news will want to stick around!
We’ve got all of the hottest stock coverage traders need to know about on Tuesday! That includes what’s going on with shares of Rubius Therapeutics (NASDAQ:RUBY), Palantir Technologies (NYSE:PLTR), and the biggest pre-market stock movers this morning. You can read all that news at the following links!
More Tuesday Stock Market News
- Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?
- Why Is Palantir Technologies (PLTR) Stock Up 13% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.